Biorez Preclinical Results to be Featured in Podium Presentation at The Orthopaedic Summit: Emerging Technologies 2020
Biorez also exhibiting its BioBrace technology at virtual booth #316 from December 9 – 12
DECEMBER 07, 2020
Biorez Inc., a New Haven startup advancing tendon and ligament repair, today announced that the results of a recently concluded preclinical study of its BioBrace™ Technology will be presented virtually at The Fellow, Resident, Medical Student Summit of the Orthopaedic Summit: Emerging Technologies (OSET) 2020 Annual Meeting. Dr. Gregory Kanski, Orthopedic Sports Medicine Fellow at UConn Health, will virtually present the preclinical research conducted at both UConn Health and Prince of Wales Hospital in Sydney, Australia.
Dr. Robert Arciero is the senior author of the presentation and the Director of the Orthopedic Sports Medicine Fellowship at UConn.
“I am delighted by Dr. Kanski’s participation in this collaborative research project and the opportunity for him to present at the conference,” said Dr. Arciero. “Overall, the study found that the BioBrace implant increased the thickness of a repaired rotator cuff tendon through the rapid induction of host generated connective tissue and was as strong as a native rotator cuff tendon by 12 weeks.”
The abstract, titled “Tissue-Engineered Augmentation of a Rotator Cuff Tendon Using A Novel Bio-Inductive Biocomposite Scaffold: A Preliminary Study In Sheep,” was selected for a podium presentation by the 2020 Program Committee after a competitive submission process. According to conference organizers, the abstract was deemed to be in the top 10% of all submissions.
“We are excited that the results of our preclinical research have been selected by the 2020 Program Committee and to have our BioBrace technology featured at a conference that is held in such high regard within the orthopedic community,” Kevin Rocco, founder and CEO. “This research project was a large collaborative effort by a world-class team of scientists, engineers, veterinarians and surgeons, and I am glad to see their work recognized.”
Additional preclinical studies are ongoing to support regulatory and commercial initiatives throughout 2021. The BioBrace implant is in the development stage and has not been approved for use by any regulatory agency, including the U.S. Food and Drug Administration.
About Biorez Inc.
Biorez is a New Haven-based medical device start-up focused on advancing tendon and ligament repair using its proprietary BioBrace™ technology. Biorez has pioneered the BioBrace™ implant, a breakthrough biocomposite scaffold featuring a highly-porous collagen sponge reinforced with bioresorbable microfilaments. The BioBrace implant is intended to reinforce soft tissue repairs in a number of clinical applications. Biorez’s products are in the development stage and have not been approved for use by any regulatory agency including the U.S. Food and Drug Administration.
Biorez Appoints Jeff Grebner as Director of Clinical AffairsNOVEMBER 01, 2021
Biorez™ Raises $3.5 Million to Close Out $7 Million in Seed FinancingSEPTEMBER 09, 2020
Biorez Hosts Grand Opening Celebration at District in New HavenDECEMBER 19, 2018